Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (manokatra rohy)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Loharanon-kevitra‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Rakitra‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (manokatra rohy)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (manokatra rohy)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Loharanon-kevitra‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Rakitra‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (manokatra rohy)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (manokatra rohy)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Loharanon-kevitra‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Rakitra‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (manokatra rohy)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (manokatra rohy)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Loharanon-kevitra‎: Blood 2003;102(4):1529-30.

Rakitra‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (manokatra rohy)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (manokatra rohy)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Loharanon-kevitra‎: Transfusion 2007;47(10):1830-6.

Rakitra‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (manokatra rohy)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (manokatra rohy)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Loharanon-kevitra‎: Iran J Blood Cancer 2009;1(4):147-50.

Rakitra‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (manokatra rohy)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (manokatra rohy)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Loharanon-kevitra‎: Int J Hematol 2012;95(1):51-6.

Rakitra‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (manokatra rohy)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (manokatra rohy)

Perrine SP.

Loharanon-kevitra‎: Pediatr Ann 2008;37(5):339-46.

Rakitra‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (manokatra rohy)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (manokatra rohy)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Loharanon-kevitra‎: Sci Rep. 2022;12(1):2752.

Rakitra‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (manokatra rohy)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (manokatra rohy)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Loharanon-kevitra‎: Haematologica 2004;89(10):1172-8.

Rakitra‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (manokatra rohy)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (manokatra rohy)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Loharanon-kevitra‎: Arch Iran Med 2009;12(3):295-7.

Rakitra‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (manokatra rohy)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (manokatra rohy)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Loharanon-kevitra‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Rakitra‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (manokatra rohy)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (manokatra rohy)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Loharanon-kevitra‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Rakitra‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (manokatra rohy)

Fetal globin gene inducers: novel agents and new potential. (manokatra rohy)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Loharanon-kevitra‎: Ann N Y Acad Sci 2010;1202:158-64.

Rakitra‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (manokatra rohy)